They found that pathogenic CHEK2 variants were the third most frequent germline alterations in both cancers (following BRCA1/BRCA2 variants); however, CHEK2 significantly prevailed in whites over blacks in both breast cancer (2.3% vs. 0.15%) and ovarian cancer (1.3% vs. 0%). This evidence concerns the gene BRCA2 and breast carcinoma.